BIOMARIN PHARMACEUTICAL INC (BMRN)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 825,410 | 745,145 | 745,740 | 712,029 |
| Selling, general and administrative | 232,279 | 206,116 | 253,480 | 263,032 |
| Research and development | 161,308 | 158,731 | 184,901 | 183,787 |
| Gain on sale of nonfinancial assets | - | - | - | - |
| Cost of sales | 150,090 | 151,558 | 188,457 | 130,459 |
| Intangible asset amortization | 4,846 | 4,847 | 5,009 | 14,299 |
| Total operating expenses | 548,523 | 521,252 | 631,847 | 591,577 |
| Income from operations | 276,887 | 223,893 | 113,893 | 120,452 |
| Interest income | 18,827 | 19,013 | 18,053 | 19,785 |
| Interest expense | 2,679 | 2,863 | 2,968 | 3,574 |
| Other income (expense), net | 4,833 | -1,954 | 5,463 | -4,527 |
| Income before income taxes | 297,868 | 238,089 | 134,441 | 132,136 |
| Provision for income taxes | 57,336 | 52,403 | 28,361 | 24,962 |
| Net income | 240,532 | 185,686 | 106,080 | 107,174 |
| Earnings per share, basic (in dollars per share) | 1.25 | 0.97 | 0.56 | 0.56 |
| Earnings per share, diluted (in dollars per share) | 1.23 | 0.95 | 0.55 | 0.55 |
| Weighted average common shares outstanding, basic (in shares) | 191,907,000 | 190,967,000 | 190,429,000 | 190,114,000 |
| Weighted average common shares outstanding, diluted (in shares) | 197,091,000 | 196,474,000 | 197,147,000 | 200,505,000 |